Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a p-glycoprotein

Drug Metabolism and Disposition

Volumn 27, Issue 5, 1999, Pages 581-587

  Kwei, Gloria Y ^a   Alvaro, R F ^a   Chen, Q ^a   Jenkins, H J ^a   Hop, C E A C ^a   Keohane, C A ^a   Ly, V T ^a   Strauss, J R ^a   Wang, R W ^a   Wang, Z ^a   Pippert, T R ^a   Umbenhauer, D R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; IVERMECTIN;

ARTICLE; BIOTRANSFORMATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

EID: 0032906888     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Beltz BS and Burd GD (1989) Immunocytochemical Techniques: Principles and Practice, p 26, Blackwell Scientific Publications, Inc., Malden, MA.
2. Chervinsky DS, Brecher ML and Hoelcle MJ (1993) Cremophor-EL enhances taxol efficacy in a multi-drug resistant C 1300 neuroblastoma cell line. Anticancer Res 13:93-96.
3. Didier AD and Loor F (1995) Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent p-glycoprotein inhibitors. Int J Cancer 43:263-267.
4. Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WJF, Eeltink C, Vermorken JB and Pinedo HM (1997) A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3:2005-2015.
5. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T and Waxman DJ (1986) Characterization of the rat and human microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
6. Habig WH, Pabst MJ and Jakoby WB (1974) Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130-7139.
7. Kolars JC, Awni WM, Merion RM and Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490.
8. Lankas GR, Cartwright ME and Umbenhauer D (1997) P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 143:357-365.
9. Lankas GR, Wise LD, Cartwright ME, Pippert T and Umbenhauer DR (1998) Placental P-glycoprotein deficiency enhances susceptibility to chemically-induced birth defects in mice. Reprod Toxicol 12:457-463.
10. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2370-2378.
11. Saeki T, Ueda K, Tanigawa Y, Hori R and Komano T (1993) Human p-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268:6077-6080.
12. Schinkel AH, Smit JJM, van Tellingen O, Beijen JH, Wagenaar E, van Deemter L, Mol CAAM, ven der Valk MA, Robanus-Maandag EC and te Riele HP (1994) Disruption of the mouse mdr1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
13. Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM and Borst P (1995) Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Invest 96:1698-1705.
14. Schuetz EG, Beck WT and Schuetz JD (1996a) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human carcinoma cells. Mol Pharmacol 49:311-318.
15. Schuetz EG, Schinkel AH, Relling MV and Schuetz JD (1996b) P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001-4005.
16. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031-2035.
17. Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ and Beare CM (1997) Identification of a p-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol 146:88-94.
18. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ and Beijen JH (1997) Enhanced oral bioavailability of paclitaxel in mice treated with the p-glycoprotein blocker SDZ PSC 833. Br J Cancer 76:1181-1183.
19. Wacher VJ, Wu CY and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
20. Wang RW, Newton DJ, Scheri TD and Lu AYH (1997) Human cytochrome P450 3A4-catalyzed testosterone 6B-hydroxylation and erythromycin N-demethylation: Competition during catalysis. Drug Metab Dispos 25:502-507.
21. Watkins PB (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Del Rev 27:161-170.
22. Webster L, Linsenmeyer MM, Morton C, Bishop J and Woodcock D (1993) Measurement of Cremophor EL following Taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85:1685-1690.
23. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M and Gomez DY (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 58:492-497.